Clinical Trial Update: This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for BT595 in chronic primary immune thrombocytopenia (ITP) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• BT595

Snippet

Sponsor: Biotest | Conditions: Immune Thrombocytopenia | Phase 3 | Status: COMPLETED